Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

PEPG

PepGen Inc

May 01 • 04:00PM ET

13.90

Dollar change +1.62
Percentage change 13.19	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM IWN VTWO IWO IWC AVSC IWV RYLD

Index	RUT	P/E	-	EPS (ttm)	-3.30	Insider Own	16.17%	Shs Outstand	32.39M	Perf Week	17.50%
Market Cap	450.22M	Forward P/E	-	EPS next Y	-2.74	Insider Trans	95.56%	Shs Float	27.15M	Perf Month	6.51%
Income	-78.63M	PEG	-	EPS next Q	-0.72	Inst Own	60.39%	Short Float	1.25%	Perf Quarter	38.58%
Sales	0.00M	P/S	-	EPS this Y	12.79%	Inst Trans	-0.43%	Short Ratio	2.93	Perf Half Y	147.77%
Book/sh	4.55	P/B	3.05	EPS next Y	4.72%	ROA	-43.62%	Short Interest	0.34M	Perf Year	-2.59%
Cash/sh	3.41	P/C	4.08	EPS next 5Y	-	ROE	-54.59%	52W Range	3.72 - 17.51	Perf YTD	104.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-172.30%	ROI	-62.64%	52W High	-20.62%	Beta	1.64
Dividend TTM	-	Quick Ratio	6.43	Sales past 5Y	0.00%	Gross Margin	-	52W Low	273.66%	ATR (14)	1.21
Dividend Ex-Date	-	Current Ratio	6.43	EPS Y/Y TTM	84.69%	Oper. Margin	0.00%	RSI (14)	58.81	Volatility	10.15% 10.39%
Employees	64	Debt/Eq	0.19	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	21.60
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	-29.94%	Payout	-	Rel Volume	1.27	Prev Close	12.28
Sales Surprise	-	EPS Surprise	13.38%	Sales Q/Q	-	Earnings	Mar 06 AMC	Avg Volume	115.47K	Price	13.90
SMA20	16.96%	SMA50	2.96%	SMA200	67.73%	Trades		Volume	146,559	Change	13.19%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-21-22	Initiated	H.C. Wainwright	Buy	$26

Apr-12-24 01:30PM	Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More (Insider Monkey)
Mar-13-24 04:05PM	PepGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-12-24 09:55AM	Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-11-24 12:00PM	PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
11:54PM	Loading…
Mar-06-24 11:54PM	PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 (InvestorPlace) -7.34%
04:01PM	PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +14.68%
Feb-20-24 08:00AM	PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Feb-07-24 07:30AM	PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock (GlobeNewswire) +17.63%
Jan-17-24 07:00AM	Mary Beth DeLena Joins PepGen as General Counsel and Secretary (GlobeNewswire)
Jan-08-24 07:00AM	PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping (GlobeNewswire)
Dec-18-23 08:00AM	PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +6.03%
Nov-15-23 08:00AM	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors (GlobeNewswire)
08:00AM	Loading…
Nov-08-23 08:00AM	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire) -10.40%
Oct-12-23 07:00AM	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +7.22%
Sep-27-23 04:16PM	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology (GlobeNewswire)
Sep-06-23 04:05PM	PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 (GlobeNewswire)
08:00AM	PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences (GlobeNewswire)
Sep-01-23 08:00AM	PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:15AM	PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-13-23 04:05PM	PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 (GlobeNewswire) +10.87%
May-31-23 11:44AM	PepGen (PEPG) Down on Clinical Hold for DM1 Candidate (Zacks) -5.07%
May-30-23 04:05PM	PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-18-23 07:00AM	PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
May-11-23 07:00AM	PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-04-23 08:00AM	PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-17-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire) +23.09%
Apr-13-23 04:05PM	PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.07%
02:25AM	Loading…
Mar-27-23 02:25AM	PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript (Insider Monkey) -16.15%
Mar-23-23 04:05PM	PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-22-23 08:00AM	PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Mar-21-23 04:05PM	PepGen to Participate in the Stifel 2023 CNS Days Conference (GlobeNewswire)
Mar-16-23 08:00AM	PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call (GlobeNewswire) +6.99%
Mar-13-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Feb-27-23 08:50AM	PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.02%
Feb-09-23 08:00AM	PepGen to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.07%
Jan-31-23 08:50AM	Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going (Zacks)
Jan-16-23 05:10AM	Companies Like PepGen (NASDAQ:PEPG) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-13-23 08:50AM	Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength (Zacks)
Dec-21-22 02:25PM	Why This PepGen Analyst Is Bullish On The Biotech Stock (Benzinga)
Dec-07-22 08:00AM	PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High? (Zacks) -6.42%
Nov-21-22 08:50AM	What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing' (Zacks) +5.54%
Nov-15-22 09:55AM	Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know (Zacks)
Nov-14-22 08:00AM	PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates (GlobeNewswire) +8.33%
Nov-10-22 08:00AM	PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.92%
Nov-08-22 08:00AM	PepGen to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Oct-13-22 01:00PM	PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress (GlobeNewswire)
Sep-28-22 01:59PM	PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst (Benzinga) +110.19%
09:25AM	PepGen Touts Encouraging Early-Stage Data From Duchenne Program (Benzinga)
06:00AM	PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-22-22 08:00AM	PepGen Appoints Habib Dable to Board of Directors (GlobeNewswire)
Sep-04-22 07:17AM	3 IPO Stocks to Watch in September (TipRanks)
Aug-12-22 08:00AM	PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -6.70%
Aug-08-22 10:51AM	We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth (Simply Wall St.)
Jul-22-22 07:45AM	PepGen Appoints Caroline Godfrey, Ph.D. to the Companys Scientific Advisory Board (GlobeNewswire)
Jun-16-22 08:30AM	PepGen Reports First Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.70%
May-27-22 05:22PM	Covetrus and PepGen Stock See Action From Activist Investors (Barrons.com) +5.63%
May-05-22 11:34PM	PepGen Announces Pricing of Initial Public Offering (GlobeNewswire)

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Feb 09 '24	Buy	10.64	2,557,593	27,212,790	9,179,273	Feb 13 04:33 PM
McArthur James G	President and CEO	Nov 30 '23	Buy	4.17	1,694	7,056	1,694	Dec 05 07:34 AM
McArthur James G	President and CEO	Jun 08 '23	Option Exercise	2.71	2,381	6,453	2,381	Jun 09 07:06 PM
McArthur James G	President and CEO	Jun 08 '23	Sale	16.04	2,381	38,188	0	Jun 09 07:06 PM
McArthur James G	President and CEO	Jun 07 '23	Option Exercise	2.71	8,419	22,815	8,419	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 07 '23	Sale	16.23	8,419	136,618	0	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 06 '23	Option Exercise	2.71	18,150	49,186	18,150	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 06 '23	Sale	16.18	18,150	293,660	0	Jun 08 05:23 PM
McArthur James G	President and CEO	Jun 05 '23	Option Exercise	2.71	500	1,355	500	Jun 06 04:19 PM
McArthur James G	President and CEO	Jun 05 '23	Sale	16.06	500	8,028	0	Jun 06 04:19 PM
McArthur James G	President and CEO	Jun 02 '23	Option Exercise	2.71	1,800	4,878	1,800	Jun 06 04:19 PM
McArthur James G	President and CEO	Jun 02 '23	Sale	16.04	1,800	28,863	0	Jun 06 04:19 PM

Open in Screener

IMRX

Immuneering Corp

May 01 • 04:00PM ET

1.53

Dollar change +0.11
Percentage change 7.75	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWM VTWO IWO CNCR IWC IWN VTWG AVSC

Index	RUT	P/E	-	EPS (ttm)	-1.89	Insider Own	29.56%	Shs Outstand	29.27M	Perf Week	2.00%
Market Cap	45.36M	Forward P/E	-	EPS next Y	-1.92	Insider Trans	-11.26%	Shs Float	20.89M	Perf Month	-38.80%
Income	-53.47M	PEG	-	EPS next Q	-0.50	Inst Own	37.97%	Short Float	13.07%	Perf Quarter	-73.94%
Sales	0.00M	P/S	-	EPS this Y	-0.36%	Inst Trans	-2.73%	Short Ratio	3.76	Perf Half Y	-74.33%
Book/sh	3.09	P/B	0.49	EPS next Y	-1.80%	ROA	-47.54%	Short Interest	2.73M	Perf Year	-85.36%
Cash/sh	2.89	P/C	0.53	EPS next 5Y	-	ROE	-53.36%	52W Range	1.38 - 11.92	Perf YTD	-79.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-57.97%	ROI	-56.44%	52W High	-87.16%	Beta	-0.60
Dividend TTM	-	Quick Ratio	11.35	Sales past 5Y	-43.59%	Gross Margin	-168734.95%	52W Low	10.87%	ATR (14)	0.25
Dividend Ex-Date	-	Current Ratio	11.35	EPS Y/Y TTM	1.47%	Oper. Margin	0.00%	RSI (14)	28.95	Volatility	11.26% 10.22%
Employees	68	Debt/Eq	0.05	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.75	Target Price	13.29
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-2.73%	Payout	-	Rel Volume	1.31	Prev Close	1.42
Sales Surprise	-	EPS Surprise	-12.34%	Sales Q/Q	-100.00%	Earnings	Mar 01 BMO	Avg Volume	725.43K	Price	1.53
SMA20	-17.91%	SMA50	-57.06%	SMA200	-76.37%	Trades		Volume	952,674	Change	7.75%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-15-24	Reiterated	Needham	Buy	$20 → $15
Mar-15-24	Downgrade	TD Cowen	Outperform → Market Perform
Mar-15-24	Downgrade	Jefferies	Buy → Hold	$16 → $3
Dec-01-23	Initiated	Needham	Buy	$20
Jun-26-23	Resumed	Oppenheimer	Outperform	$25
Apr-19-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight	$5 → $14
Apr-19-23	Upgrade	Mizuho	Neutral → Buy	$10 → $20
Mar-30-23	Initiated	Mizuho	Neutral	$10
Feb-03-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$12 → $5
Jul-08-22	Initiated	Chardan Capital Markets	Buy	$18
Apr-01-22	Initiated	Oppenheimer	Outperform	$25
Jan-07-22	Initiated	Piper Sandler	Overweight	$41

Show Previous Ratings

Apr-09-24 12:00PM	IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models (GlobeNewswire)
Apr-03-24 04:05PM	Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 08:00AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire)
Mar-18-24 11:02AM	Immuneering (IMRX) Plummets 71% in One Week: Here's Why (Zacks) +34.03%
Mar-14-24 07:00AM	Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors (GlobeNewswire) -50.68%
08:00AM	Loading…
Mar-12-24 08:00AM	Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors (GlobeNewswire)
Mar-11-24 08:00AM	Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors (GlobeNewswire) -9.53%
Mar-06-24 08:00AM	Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning (Newsfile)
Mar-05-24 05:00PM	Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Immuneering to Participate in the Cowen 44th Annual Health Care Conference (GlobeNewswire)
Mar-03-24 07:01PM	Immuneering Corp (IMRX) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com)
Mar-01-24 08:00AM	Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-20-24 08:00AM	Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer (GlobeNewswire)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +8.00%
Feb-01-24 08:00AM	Immuneering Announces Participation in February Investor Conferences (GlobeNewswire)
08:00AM	Loading…
Dec-12-23 08:00AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations (GlobeNewswire) -7.11%
Nov-20-23 04:05PM	Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-09-23 04:05PM	Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire) -11.86%
Oct-12-23 04:05PM	Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference (GlobeNewswire) -6.65%
Oct-04-23 04:05PM	Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-23 08:00AM	Immuneering to Present at the Morgan Stanley Healthcare Conference (GlobeNewswire)
Aug-03-23 04:05PM	Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-02-23 06:09AM	Immuneering Corporation (NASDAQ:IMRX) insiders have significant skin in the game with 28% ownership (Simply Wall St.)
Jul-05-23 09:55AM	Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet (Zacks)
Jun-05-23 08:00AM	Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors (GlobeNewswire)
May-30-23 08:00AM	Immuneering to Present at the Jefferies Healthcare Conference (GlobeNewswire) +6.86%
May-04-23 07:25PM	Immuneering Corporation (IMRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -8.75%
04:05PM	Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-18-23 09:24AM	Immuneering Announces $30 Million Underwritten Offering (GlobeNewswire) +9.60%
09:00AM	Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline (GlobeNewswire)
04:20AM	Loading…
04:20AM	Morphic Holding, Inc. (MORF) Moves 22.5% Higher: Will This Strength Last? (Zacks)
Apr-12-23 04:05PM	Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Apr-11-23 03:56AM	Immuneering Corporation (IMRX) Surges 18.5%: Is This an Indication of Further Gains? (Zacks) +5.78%
Apr-05-23 08:00AM	Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Mar-28-23 08:00AM	Immuneering Appoints Harold E. Brakewood as Chief Business Officer (GlobeNewswire) -7.40%
Mar-27-23 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 102.51%: Here's is How to Trade (Zacks)
Mar-24-23 01:25PM	Why Shares of Immuneering Jumped This Week (Motley Fool)
Mar-23-23 06:18AM	Immuneering Corporation (IMRX) Soars 16.9%: Is Further Upside Left in the Stock? (Zacks)
Mar-14-23 04:30PM	Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire) +5.62%
Mar-09-23 09:55AM	Does Immuneering Corporation (IMRX) Have the Potential to Rally 210.19% as Wall Street Analysts Expect? (Zacks) +5.47%
Mar-08-23 07:14AM	Immuneering Corporation (NASDAQ:IMRX) Q4 2022 Earnings Call Transcript (Insider Monkey) +22.87%
Mar-06-23 05:45PM	Immuneering Corporation (IMRX) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-05-23 06:30PM	Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity (GlobeNewswire)
Feb-28-23 08:00AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire)
Feb-27-23 08:00AM	Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Feb-05-23 07:18AM	Immuneering Corporation (NASDAQ:IMRX) insiders, who hold 31% of the firm would be disappointed by the recent pullback (Simply Wall St.)
Jan-31-23 06:50AM	Immuneering To Present at Guggenheim 2023 Oncology Conference (GlobeNewswire)
Nov-28-22 06:50AM	Immuneering Announces First Patient Dosed in its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Nov-16-22 06:35AM	Immuneering Third Quarter 2022 Earnings: Revenues Disappoint (Simply Wall St.)
Nov-10-22 10:15AM	Immuneering Corporation (IMRX) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
09:00AM	Immuneering Reports Third Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
09:00AM	Immuneering Presents Promising Preclinical Data on its Second Program IMM-6-415 at the 37th Annual Meeting of SITC (GlobeNewswire)
Nov-03-22 06:50AM	Immuneering Announces Participation in November Investor Conferences (GlobeNewswire) -12.80%
Oct-20-22 06:50AM	Immuneering Appoints Leah R. Neufeld as Chief People Officer (GlobeNewswire)
Oct-05-22 08:05AM	Immuneering To Present Poster on IMM-6-415 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) -5.80%
Sep-30-22 12:00PM	What Makes Immuneering Corporation (IMRX) a New Buy Stock (Zacks) +9.15%
06:50AM	Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire)
Sep-12-22 09:55AM	Wall Street Analysts See a 148% Upside in Immuneering Corporation (IMRX): Can the Stock Really Move This High? (Zacks) +10.82%
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Sep-02-22 08:09AM	Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations (GlobeNewswire) +7.05%
Aug-25-22 09:55AM	Wall Street Analysts Believe Immuneering Corporation (IMRX) Could Rally 224%: Here's is How to Trade (Zacks) -7.35%
06:50AM	Immuneering Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-10-22 05:55PM	Immuneering Corporation (IMRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Immuneering Reports Second Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-08-22 12:24PM	Immuneering (NASDAQ:IMRX) shareholders have endured a 77% loss from investing in the stock a year ago (Simply Wall St.) +11.25%
Jul-22-22 10:01AM	Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock? (Zacks)
Jul-11-22 07:57AM	What Type Of Shareholders Own The Most Number of Immuneering Corporation (NASDAQ:IMRX) Shares? (Simply Wall St.)
Jul-08-22 11:40AM	Why This Small-Cap Stock Is Gaining More Than 10% Today? (Benzinga) +28.85%
Jul-06-22 06:50AM	Immuneering Announces Participation in William Blair Biotech Focus Conference 2022 (GlobeNewswire) +5.80%
May-26-22 05:26PM	Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104 (GlobeNewswire) +11.31%
May-20-22 06:50AM	Immuneering Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-10-22 06:30AM	Immuneering Reports First Quarter 2022 Financial Results and Recent Business Highlights (GlobeNewswire) +13.99%
May-09-22 08:54AM	Immuneering Corporation (NASDAQ:IMRX) insiders placed bullish bets worth US$10.0m in the last 12 months (Simply Wall St.) -12.63%
May-05-22 06:50AM	Immuneering Announces Participation in Citis Biopharma VIRTUAL Co-Panel Day (GlobeNewswire) -8.36%
Apr-07-22 10:46AM	Oppenheimer Sees Gains of Over 100% in These 3 Beaten-Down Stocks (TipRanks) +5.09%
Apr-01-22 06:50AM	Immuneering Announces Participation in Piper Sandler AI/ML Investor Conference (GlobeNewswire) +14.99%
Mar-24-22 06:55AM	Immuneering Announces Participation in the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-10-22 08:46AM	Is a Surprise Coming for Immuneering (IMRX) This Earnings Season? (Zacks)
06:30AM	Immuneering Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-24-22 06:50AM	Immuneering Announces Participation in March Investor Conferences (GlobeNewswire) +5.46%
Feb-07-22 08:30AM	Should You Buy Immuneering (IMRX) Ahead of Earnings? (Zacks)
Jan-31-22 12:24PM	What Is The Ownership Structure Like For Immuneering Corporation (NASDAQ:IMRX)? (Simply Wall St.)
Jan-24-22 06:50AM	Immuneering Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-19-22 08:00AM	PepGen Appoints Laurie Keating as Chair of Board of Directors (GlobeNewswire)
Jan-18-22 06:50AM	Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D. (GlobeNewswire)
Jan-06-22 04:10PM	Immuneering Reports Compelling Preclinical Data on IMM-1-104 in NRAS Mutant Melanoma Model And Will Host Key External Expert Investor Event (GlobeNewswire) -8.66%
Jan-03-22 06:50AM	Immuneering Appoints Rimma Steinhertz, Ph.D., PMP as Vice President, Project and Alliance Management (GlobeNewswire) +5.07%
Dec-16-21 06:50AM	Immuneering Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Nov-18-21 06:35AM	Immuneering Announces Participation in December Investor Conferences (GlobeNewswire)
Nov-10-21 06:50AM	Immuneering to Participate in Jefferies 2021 London Healthcare Conference (GlobeNewswire)
Nov-09-21 06:30AM	Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-01-21 09:20AM	Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth (Simply Wall St.)
Oct-11-21 06:50AM	Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -18.44%
Oct-01-21 06:50AM	Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +8.85%
Sep-20-21 04:10PM	Immuneering Announces Inclusion in the Russell 2000® Index (GlobeNewswire) -11.27%
Sep-09-21 06:30AM	Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-02-21 04:05PM	Immuneering to Participate in September Investor Conferences (GlobeNewswire)
Aug-03-21 04:07PM	Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters Option to Purchase Additional Shares (GlobeNewswire) +12.76%
Jul-30-21 02:24PM	Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO (Benzinga)

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cormorant Asset Management, LP	10% Owner	Apr 01 '24	Sale	2.90	400,000	1,160,181	2,895,273	Apr 03 05:37 PM
Feinberg Peter	Director	Mar 22 '24	Buy	2.55	25,000	63,713	111,766	Mar 25 09:13 AM
Brakewood Harold Eugene	Chief Business Officer	Mar 22 '24	Buy	2.57	3,900	10,015	3,900	Mar 25 09:10 AM
Schall Thomas J.	Director	Mar 22 '24	Buy	2.55	2,900	7,385	2,900	Mar 25 04:03 PM
Morales Mallory	Chief Accounting Officer	Mar 22 '24	Buy	2.55	393	1,000	8,278	Mar 25 09:04 AM
Morales Mallory	Chief Accounting Officer	Mar 21 '24	Buy	2.72	1,107	3,009	7,885	Mar 25 09:04 AM
Hall Brett Matthew	CHIEF SCIENTIFIC OFFICER	Mar 20 '24	Buy	2.86	7,000	20,020	345,896	Mar 21 09:06 AM
Neufeld Leah R	CHIEF PEOPLE OFFICER	Mar 20 '24	Buy	2.88	3,818	10,993	10,029	Mar 21 09:11 AM
Feinberg Peter	Director	Mar 19 '24	Buy	2.56	25,000	64,000	86,766	Mar 19 07:04 PM
Zeskind Benjamin J.	PRESIDENT AND CEO	Mar 19 '24	Buy	2.77	20,000	55,326	2,281,852	Mar 19 06:59 PM
BERMAN ANN E	Director	Mar 18 '24	Buy	2.13	57,965	123,436	67,465	Mar 19 07:10 PM
Feinberg Peter	Director	Mar 18 '24	Buy	2.38	50,000	119,058	61,766	Mar 19 07:04 PM
Cormorant Asset Management, LP	10% Owner	Mar 15 '24	Sale	2.14	400,000	856,400	3,295,273	Mar 18 05:59 PM
Cormorant Asset Management, LP	10% Owner	Mar 14 '24	Sale	3.72	509,091	1,892,603	3,695,273	Mar 18 05:59 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

PEPG

PepGen Inc

IMRX

Immuneering Corp

Upgrade your FINVIZ experience